Table 2.
Characteristics of subjects with endpoint isolates who had clustered versus unique isolates
| Characteristica | Patients with: |
Pb | |
|---|---|---|---|
| Clustered isolates (n = 56) | Unique isolates (n = 25) | ||
| Median age (yrs) | 35 | 32 | 0.79 |
| No. of male subjects (%) | 11 (20) | 8 (32) | 0.23 |
| Baseline CD4 count (median cells/μl) | 348 | 342 | 0.79 |
| Baseline HIV viral load (mean log10)c | 4.4 | 4.3 | 0.63 |
| No. of subjects (%) with prior treatment for tuberculosis | 11 (20) | 4 (16) | 0.70 |
| Baseline ART (no.) | 0 | 0 | |
| TST ≥ 5 mm, no. (%)d | 33 (60) | 19 (76) | 0.16 |
| No. of subjects (%) that received isoniazid | 28 (50) | 13 (52) | 0.87 |
| No. of subjects (%) that received M. vaccae vaccine | 25 (45) | 9 (36) | 0.47 |
a
ART, antiretroviral therapy; TST, tuberculin skin test.
b
P values were determined by using the Mann-Whitney U test, Student t test, and chi-squared analyses as appropriate.
c
n = 53.
d
n = 55 clustered; n = 25 unique.